

TARGETED GENETICS CORP /WA/

Form 8-K

November 30, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K  
CURRENT REPORT**

**Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)

**November 28, 2005**

**Targeted Genetics Corporation**

(Exact name of registrant as specified in its charter)

**Washington**

**0-23930**

**91-1549568**

(State or other jurisdiction  
of incorporation)

(Commission File  
Number)

(IRS Employer  
Identification No.)

**1100 Olive Way, Suite 100, Seattle, Washington**

**98101**

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code

**(206) 623-7612**

**Not Applicable**

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On November 28, 2005, Targeted Genetics Corporation and its scientific collaborators at The Children's Hospital of Philadelphia and Columbus Children's Research Institute announced that the National Institute of Allergy and Infectious Disease has awarded a \$21.75 million contract to expand AAV-based HIV vaccine development, of which Targeted Genetics as a subcontractor is eligible to receive up to \$18 million over 5 years to be used to advance AAV-based vaccines against HIV. A copy of Targeted Genetics' press release announcing the contract award is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

99.1 Press Release Dated November 28, 2005

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Targeted Genetics Corporation

By: /s/ H. Stewart Parker  
H. Stewart Parker  
President and Chief Executive Officer

Dated: November 30, 2005

3

---

EXHIBIT INDEX

99.1 Press Release Dated November 28, 2005

4